New Herceptin early breast cancer regimens

Copyright © F. Hoffmann-La Roche Ltd
Copyright © F. Hoffmann-La Roche Ltd

Herceptin (trastuzumab) has had its licence for use in HER2-positive early breast cancer extended.

In addition to use following surgery, chemotherapy and radiotherapy, it is now also recommended in:

  • combination with paclitaxel or docetaxel following adjuvant chemotherapy with doxorubicin and cyclophosphamide, or;
  • combination with docetaxel and carboplatin.

In early breast cancer patients, cardiac monitoring should be performed before treatment initiation, every 3 months during treatment and every 6 months for 2 years from the last dose of Herceptin.

View Herceptin drug record

Further Information: Roche Products Ltd


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases